2,490 results found

In particular, these food service establishments will be required to display the number of calories in each size and variety of food and drink item offered, as well as "any other information" required by the regulations.

The Court found that Mylan's allegation of invalidity on the basis of obviousness was justified.

On April 28, 2017, the Federal Court released a Notice to the Parties and the Profession: Trial Management Guidelines.

The Therapeutic Products Directorate, the Biologic and Radiopharmaceutical Drugs Directorate and the Natural and Non-Prescription Health Products Directorate have released their Drug Submission Performance Annual Reports ...

Health Canada has issued updated guidance reflecting the September 21, 2017 amendments: Guidance Document: Patented Medicines (Notice of Compliance) Regulations (see our summary of the amendments here).

On June 27, 2019, Health Canada published Drug and medical device highlights 2018: Helping you maintain and improve your health, an annual highlights report for 2018.

The Standing Committee on Health (HESA) of the House of Commons met on Thursday, April 27, 2023, to begin its study of the Patented Medicine Prices Review Board (PMPRB).

On March 30, 2020, Kennedy and Janssen applied to the Supreme Court of Canada for leave to appeal a Federal Court of Appeal decision relating to Kennedy's patent covering uses of REMICADE...

On April 5, 2024, the pan-Canadian Pharmaceutical Alliance (pCPA) announced that it was ready to accept drugs through the pCPA Temporary Access Process (pTAP) (see our previous article regarding the consultation).

Manitoba has implemented a Biosimilars Initiative effective August 1, 2024. Manitoba is the last province in Canada to implement a biosimilar policy that requires patients receiving funding under the Manitoba Pharmacare...

On April 1, 2022, the Board announced it will hold a public rehearing of the matter.

As previously reported, the 2018 Federal Budget announced the creation of an Advisory Council on the Implementation of National Pharmacare.

For complete details about these proceedings, click here.

These changes are summarized in CDR Update – Issue 138, and will be enforced for all submissions and resubmissions received on or after July 27, 2018.

Eliminate the requirement for filing clinical case reports in a filed submission or supplement, unless requested by the Minister, in order to alleviate administrative burden.

We reported on the six Federal Court and three FCA PMNOC Regulations decisions publicly released in 2017.

The September NEWSletter also provides information about the PMPRB’s participation in past and future events, as well as NPDUIS research initiative and activities.

On August 20, 2018, the Federal Court dismissed Valeant's PMNOC application regarding Ranbaxy's bupropion extended-release tablets and Patent No. 2,524,300.